Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Recruiting

Phase 3

AXS-14Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Sponsor:

Axsome Therapeutics, Inc.

Code:

NCT07398417

Conditions

Fibromyalgia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AXS-14 (Esreboxetine)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-05. This information was provided to ClinicalTrials.gov by Axsome Therapeutics, Inc. on 2026-02-09.